Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.

Sail Biomedicines, a Flagship Pioneering company, is generating tomorrow’s medicines today through the language of life. Sail’s platform combines first-in-category translatable circular RNA technology (Endless RNA™ or eRNA™), and proprietary programmable nanoparticles, utilizing natural components, to comprehensively program medicines for the first time. By leveraging its rapid prototyping and testing bioplatform, Sail is building a wealth of data, enabling unparalleled use of state-of-the-art AI techniques for the integrative design of RNA medicines with unprecedented performance and broad applicability. For more information, visit  https://www.sail.bio/

Veridix AI is the technology, data and AI arm of the Emmes Group, dedicated to pioneering advancements in AI and patient-centric technologies. The name Veridix AI has its roots in 'Verus', the Latin word for "truth", and '-dix' for "data", "insights", and "experience". Taken together, Veridix AI collectively symbolizes our dedication to delivering meaningful, patient- focused solutions through technology, data, and insights. Veridix AI, part of Emmes Group, where human intelligence meets artificial intelligence. For more information, go to https://veridixai.com/

Bionical Emas is the only Contract Research Organization to combine Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP). Their unique integrated business model, with its range of services and capabilities, benefit many of the world’s leading pharma and biotech companies. This distinctive offering enables them to maximize access and evidence generation at every stage of the drug development pathway. With extensive experience across all phases of clinical research, they have a rich history in rare diseases, oncology/heme-oncology, and infectious diseases.

Patient centricity is fundamental to the work they do at Bionical Emas. Focused on ensuring the patient voice is always represented, their goal is to create a positive patient journey and reduce burden where possible when designing clinical trials or early access programs. To learn more, please visit https://bionicalemas.com/

Uneedle is a pioneering company specializing in the design and manufacturing of silicon microneedles for intradermal and suprachoroidal injections. With ISO13485 certification, we leverage advanced semiconductor manufacturing processes to deliver precise, atom-sharp needles, ideal for applications ranging from vaccine delivery to ophthalmic treatments. Our microneedles enable more efficient drug delivery, reduce patient discomfort, and are compatible with standard medical devices. Uneedle's innovative platform is CE-marked, FDA-approved, and supports pharmaceutical partners in co-developing novel therapies, ensuring scalability and superior performance. Based in the Netherlands, we bring the best of high-tech, GMP-compliant cleanroom production to healthcare innovation. To learn more, please visit https://www.uneedle.com/

PSN Labs is your full-service partner for engineering and product development, specializing in drug delivery solutions. From concept to commercialization, we manage every step, ensuring risk mitigation and optimization through virtual and physical processes. Our ISO 17025 Testing Lab offers biocompatibility testing, drug stability assessments, and regulatory consulting. With ISO 13485-certified molding facilities equipped with cleanroom capabilities, we streamline manufacturing and functional prototyping. Consolidating services with PSN Labs saves time, costs, and ensures the highest quality standards are met, providing a hassle-free experience for our clients. To learn more, please visit https://www.psnlabs.com/

Shaily is a leading manufacturer specializing in the design and manufacturing of high-quality pens and autoinjectors for the pharmaceutical and medical device sectors. Our state-of-the-art manufacturing facilities are equipped with cutting-edge technology and automation, ensuring the highest standards of quality, reliability, and safety in every product we produce. We adhere to the ISO 15378 and 13485 Medical Device Single Audit Program (MDSP) Quality Management System (QMS) which demonstrates our dedication to maintaining rigorous quality control throughout our entire process and supports its customers with DMF, NDA, ANDA, and 510k filings from design and development to production and post-market activities. For more information, visit https://www.shaily.com/

Our 30 years of experience (GLP/GCP/GMP) in the development of complex dosage forms helps to drive our partner’s programs forward daily. With specialist expertise in orally inhaled & nasal drug product development (OINDPs), we provide analytical testing integrated with formulation and clinical manufacturing capabilities, to support a wide range of projects. Our expertise covers small and large molecules - where we have a dedicated facility for biologics characterisation - and selecting the right delivery platform and device technology to suit your needs. Our expert analytical services include specific aerosol testing for OINDPs, as well as characterisation and QC testing for various classes of molecules, including DNA therapies, peptides, cell & gene therapies, liposomes, nanoparticles and vaccines. We can also run E&L studies and provide regulatory services through our network of laboratories and consultants. For more information, visit https://www.intertek.com/pharmaceutical/melbourn/

OncoLize develops injectable drug depots for localized, intra-tumoral drug-delivery. The company demonstrates precision: 125x higher drug concentration at target, much smaller doses in total, very low drug levels outside the tumor… Strong pre-clinical P-o-C with 100% survival in vivo with pancreatic-cancer and lung-cancer. Raising €2.5 to finalize pre-clinical early 2025; Series A of €10-15 mln early 2026. Next: Lung, Colon, Breast, Bladder, Prostate.  To learn more, please visit https://oncolize.com/

myTomorrows' mission is to enable earlier and better access to all possible treatment options. We aim to break barriers for eligible patients to receive information on and enroll in clinical trials and expanded access programs by providing a single digital platform to connect all stakeholders of pre-approval access. To learn more, please visit https://mytomorrows.com/

Vetter is a leading fill and finish CDMO headquartered in Ravensburg, Germany. Pharmaceutical and biotech companies worldwide rely on Vetter's decades of experience, high quality, and state-of-the-art technologies. Vetter provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for various injection systems. With innovative solutions, Vetter develops prefilled drug delivery systems and processes to continuously improve patient safety, comfort, and compliance. To learn more, please visit https://www.vetter-pharma.com

MilliporeSigma, a life science leader, is a business of Merck KGaA, Darmstadt, Germany. We provide excipients, APIs, and critical raw material as well as contract testing, development and manufacturing services to support all stages of your drug manufacturing process. Benefit from application know-how and global support. To learn more, please visit https://www.sigmaaldrich.com/